Navigation Links
Semafore Broadens Pipeline With Multi-Targeted Kinase Inhibitors
Date:8/26/2008

aft models demonstrated 81 percent tumor growth inhibition. SF2506 testing resulted in 93 percent tumor growth reduction in the same model.

"Semafore's proprietary kinase scaffold and our new multi-targeted kinase inhibitors add significant value to our pipeline," said Dr. Dennis McKeever, Semafore's Chief Executive Officer. "In addition to inhibiting all Class I isoforms of PI3K, our compounds SF2506 and SF2523 block additional key kinases which is in keeping with the multi-targeting philosophy behind other recent successful molecularly targeted agents."

About Semafore

Semafore is a clinical stage drug discovery and development company focused on small molecule modulators of the PI3 kinase and PTEN cell signaling pathway, a promising target pathway for multiple disorders, including the company's focus -- cancer. Semafore is a leader in the development of PI3K inhibitors and one of the first biopharmaceutical companies to focus on both PI3K and PTEN. The company has successfully discovered and is developing a portfolio of drug candidates addressing these targets.

About SF1126

There is a strong and significant biological rationale for developing PI3 kinase inhibitors to treat cancer. Phosphoinositide 3-kinase (PI3K) is the gate keeper of one of the major pathways of intracellular signal transduction that regulates cell growth, proliferation, angiogenesis, migration, differentiation, and survival. Dysregulation of the PI3K signaling pathway is believed to play an integral role in the genesis of many cancers including both solid tumors and hematologic malignancies. Cancer research and pharmaceutical drug development efforts have been aimed at discovering and developing therapeutics that inhibit PI3K with the hope of controlling cancer cell division, angiogenesis (the formation of new blood vessels for cancer growth), proliferation and metastasis. Semafore's innovative PI3K inhibitor, SF1126, promises such hope for cancer patients. '/>"/>

SOURCE Semafore Pharmaceuticals Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Semafore Pharmaceuticals Reports Positive Interim Results from a Phase I Study of SF1126, a Targeted Pan-PI3K Inhibitor, in Patients with Advanced Solid Tumors
2. Semafores PI3 Kinase Inhibitor SF1126 is a Vascular Targeted Conjugate in Phase I Clinical Trials in Solid Tumors and Multiple Myeloma
3. Semafores SF1126 Exhibits Antitumor and Antiangiogenic Activity
4. Semafores PI3 Kinase Inhibitor SF1126 is Active Against Tumor and Tumor Cells and Synergizes with Standard Chemotherapy Agents
5. FDA Broadens US Indication for Once-Yearly Reclast(R) as Only Osteoporosis Treatment Approved for Prevention of Fractures After a Hip Fracture
6. Medarex Highlights Strength in Antibody Development and Underlying Pipeline Strategy at R&D Day Event in New York City
7. The Ocean Becomes a Pipeline To A Cure for Cystic Fibrosis
8. Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting
9. Intercell AG to Acquire Iomai Corporation to Expand Late Stage Product Pipeline and Strengthen Leadership in Vaccine Innovation
10. Shire Enhances its Orphan Drug Pipeline With the Acquisition of a New Clinical Candidate for Metachromatic Leukodystrophy
11. SuperGen to Highlight Oncology Pipeline Data in Multiple Presentations at the AACR Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/1/2015)... , April 1, 2015  Salix Pharmaceuticals, Ltd. ... International, Inc. (NYSE: VRX ) (TSX:VRX), today ... outstanding $750,000,000 aggregate principal amount of its 6.00% ... (the " Notes ") pursuant to two redemptions. ... aggregate principal amount of the Notes, and on ...
(Date:4/1/2015)... 2015  Daiichi Sankyo, Inc., the US subsidiary of ... merge with its US-based sister company, Asubio Pharmaceuticals, Inc.  ... integrated into the Daiichi Sankyo global development organization, led ... Asubio Pharmaceuticals, parent company, Asubio Pharma Co., Ltd, ... will continue to operate as a wholly owned subsidiary ...
(Date:4/1/2015)... , April 1, 2015 Valeant Pharmaceuticals International, ... today announced the expiration of the tender offer (the ... to purchase all of the outstanding shares of Salix ... price of $173.00 per share in cash, without interest, ... midnight, Eastern time, on April 1, 2015.  Valeant expects ...
Breaking Medicine Technology:Redemption of All of Salix's Outstanding 6.00% Senior Notes due 2021 2Redemption of All of Salix's Outstanding 6.00% Senior Notes due 2021 3Daiichi Sankyo, Inc. and Asubio Pharmaceuticals, Inc. Merge 2Valeant Pharmaceuticals International, Inc. Completes Tender Offer For Salix Pharmaceuticals, Ltd. 2Valeant Pharmaceuticals International, Inc. Completes Tender Offer For Salix Pharmaceuticals, Ltd. 3
(Date:4/1/2015)... 2015 BioPlus Specialty Pharmacy ... has released a new app to keep health care ... chronic hepatitis C virus (HCV) infection. This ‘HCV Treatment ... from the American Association for the Study of Liver ... new direct-acting oral medications to treat HCV have been ...
(Date:4/1/2015)... Dr. Daniel C. Stewart will be ... the benefits of the LANAP® treatment over traditional ... People who live in Howard County, and surrounding areas ... visit Dr. Stewart, a Maryland dentist, for a minimally ... protocol, which is a laser gum surgery procedure, Dr. ...
(Date:4/1/2015)... 2015 OSF Saint Paul Medical Center, ... , was welcomed into the Ministry April 1, 2015, ... Paul E. Showalter, vicar general of the Catholic Diocese ... culminated a nearly year-long transition process for the former ... Speakers for the morning ceremony included Sister Judith Ann ...
(Date:4/1/2015)... 2015 Aging2.0 , the global ... the launch of the Aging2.0 Alliance – ... and technology companies. The announcement was made today at ... Business Strategies Forum in San Diego, CA. ... program is now open for additional members. “This is ...
(Date:4/1/2015)... April 01, 2015 Dr. Rod ... Distinguished Teaching Professor of the Department of Plastic Surgery ... doctors to review reports of blindness resulting from the ... . The group published their study, along with ideas ... Surgery journal. , "We began to see increasing reports ...
Breaking Medicine News(10 mins):Health News:BioPlus Specialty Pharmacy Releases ‘HCV Treatment Path’ App for Hepatitis C Providers 2Health News:Dr. Daniel C. Stewart Offers Columbia Area Residents an Informational Seminar in April About Less Invasive Gum Disease Treatment Now Available at Smile Savers Dentistry 2Health News:Dr. Daniel C. Stewart Offers Columbia Area Residents an Informational Seminar in April About Less Invasive Gum Disease Treatment Now Available at Smile Savers Dentistry 3Health News:Mendota Community Hospital Now OSF Saint Paul Medical Center 2Health News:Mendota Community Hospital Now OSF Saint Paul Medical Center 3Health News:Aging2.0 Announces Launch of New Membership Community, Aging2.0 Alliance 2Health News:Aging2.0 Announces Launch of New Membership Community, Aging2.0 Alliance 3Health News:Aging2.0 Announces Launch of New Membership Community, Aging2.0 Alliance 4Health News:Dr. Rod J. Rohrich and Colleagues Study Rare Occurrences of Blindness Caused by Use of Facial Fillers 2Health News:Dr. Rod J. Rohrich and Colleagues Study Rare Occurrences of Blindness Caused by Use of Facial Fillers 3
... Eldik, director of the University of Kentucky Sanders-Brown Center on ... research into a possible treatment for Alzheimer,s disease. The grant ... Foundation, and was one of only eight Awards in Alzheimer,s ... in 2010. Van Eldik,s research project focuses on developing ...
... MONDAY, Jan. 24 (HealthDay News) -- The anti-estrogen drug that ... also reduce the risk of dying from lung cancer, researchers ... online edition of the journal Cancer , tamoxifen lowered ... already had breast cancer. However, the results are too ...
... This release is available in French . ... Timothy Geary received a $1-million grant today for landmark ... African biodiversity. Grand Challenges Canada, Canada,s International Development ... the Bill & Melinda Gates Foundation have joined together ...
... Reinberg HealthDay Reporter , SUNDAY, Jan. 23 (HealthDay ... may be delayed until the end of this week because ... said Saturday. Dr. John Holcomb, a trauma surgeon and ... have to decide whether a catheter draining the fluid can ...
... -- By this point, New Year,s resolutions might be a ... fine-tuning, especially for those who resolved to lose weight. ... Denver, suggests using what she calls the "SMART" system to ... for goals that are specific, measurable, attainable, realistic and timely. ...
... deciphered the genetic code for a type of pancreatic cancer, ... in the Jan. 20 issue of Science Express, ... twice as long as those without them. "One of ... with this kind of rare cancer has a unique genetic ...
Cached Medicine News:Health News:Breast Cancer Drug May Also Help Lung Cancer Patients 2Health News:McGill awarded $1-million grant to address debilitating parasitic diseases in the developing world 2Health News:McGill awarded $1-million grant to address debilitating parasitic diseases in the developing world 3Health News:Rep. Giffords Set to Begin Rehab in Houston 2Health News:Rep. Giffords Set to Begin Rehab in Houston 3Health News:Rep. Giffords Set to Begin Rehab in Houston 4Health News:How to Get Smart About Weight Loss 2Health News:Johns Hopkins scientists crack genetic code for form of pancreatic cancer 2Health News:Johns Hopkins scientists crack genetic code for form of pancreatic cancer 3
Provides quick access to information needed to make diagnoses and treatment decisions....
PDA format of the well-known standard antimicrobial reference....
PDA application containing all 7,000+ Physicians' Current Procedural Terminology codes developed by the American Medical Association....
PDA application providing a complete guide for the diagnosis and management of electrolyte disorders....
Medicine Products: